Eli Lilly and Company (LLY) on Thursday announced positive results from a Phase 2 trial evaluating eloralintide in adults with obesity or overweight.
The study achieved its primary endpoint, showing mean weight reductions ranging from 9.5% to 20.1%, compared with 0.4% for placebo.
Lilly said it plans to initiate Phase 3 studies of eloralintide as a monotherapy for obesity treatment by the end of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.